Career

Hubert Caron: I’ve Retired from Roche-Genentech but I’m Still Driven to Cure Children

Hubert Caron/accelerate-platform.org

Aug 10, 2025, 06:25

Hubert Caron: I’ve Retired from Roche-Genentech but I’m Still Driven to Cure Children

Hubert Caron, Former Group Medical Director at Roche-Genentech, shared a post on LinkedIn:

“I wanted to share that I have retired from Roche-Genentech at July 31st, 2025.

To be clear: I am only retiring from Roche, I am not retiring my brain, nor am I retiring my motivation to contribute to curing more children with cancer globally.

My 11 years at Roche, leading the iPODD team for innovative Pediatric Oncology Drug Development, were full of learnings, achievements and shared purpose with inspiring colleagues, amazing collaborators and other motivating stakeholders to enable an impactful development of the Roche Oncology portfolio for children with cancer.

Some achievements of the iPODD Pediatric Oncology team, realized by strong collaboration with academic colleagues all over the world, with close connections to patient advocates and by recurrent constructive interactions with FDA, EMA (PDCO / CHMP):

Approved indications for drugs for use in children with cancer:

Rituxan approval in 1L pediatric BNHL, leading (in combination with chemo) to a cure rate of 96% for thousands of children per year in US + Europe
Tecentric approval for adolescent ASPS
Rozlytrek approval for NTRK+ solid tumors including children

Compliance with Peds Regulations for all molecules in the Roche Oncology portfolio, allowing for smooth adult development:

Large number of pediatric plans (PIP/iPSP) with active development in children
Pediatric waivers supported by pediatric science for even more molecules

The iPODD team established itself as global leader in drug development for Pediatric Oncology.

To all people I have worked with in the past 11 years: I have enjoyed collaborating with all of you to realize succesful outcomes for children with cancer, I have learned a lot from you, I have been motivated enormously by you, I have been impressed by your knowledge, capabilities, creativity, resilience and your never ending motivation.

I am looking forward to a next chapter in my professional and personal life with new activities both inside and outside the world of drug development for children with cancer and hope our paths will cross again.”

More Posts Featuring Roche.